definiens: means all tangible and intangible : ( a ) information, techniques, technology, practices, trade secrets, inventions, methods, knowledge, kno w - how, skill, experience, data, results ( including ph armacological, toxicological, and clinical test dat a and results, research data, reports and batch records ), preformu lation, formulation, analytical and quality control data, analytical methods, full batch documentation, packa ging records, release, stability, storage and shelf -life data, and manufacturing process information, results or d escriptions, software and algorithms ; and / or ( b ) compositions of matter, cells, cell lines, assa ys, animal models and physical, biological or chemi cal materials, 2.17 means the gross amount of monies or cash equivalent or other consideration th at is collected by Licensee, Affiliate, or Sublicensees f rom unrelated third parties for sale or transfer of Licensed Products, less [ * * * ] . No other deductions shall be made for commissions paid to individuals whether th ey be with independent sales agencies or regularly employ ed by Licensee or Sublicensees or on its payroll . A transfer of Licensed Product to a Sublicensee or Affiliate f or end use but not resale by the Sublicensee or Aff iliate shall be treated as a collection by Licensee at the list price of the Licensee in an arm’s- length transacti on . In the event that a Licensed Product is sold for a single price in combination with another ingredient, product or service ( a ), for which no royalty would be due hereunder if sold separately, Net Sales Reve nue shall be calculated, on a country by country basis, by multiplying the Net Sales Revenue of the Combin ation Product by the fraction A/(A + B ), where A is the a verage gross selling price during the previous cale ndar half of the Licensed Product sold separately and B is the a verage gross selling price during the previous cale ndar half of the therapeutically active pharmaceutical ingredien t, product or service . In the event that the Licens ed Product is sold separately during the previous calendar half a nd the other active ingredient, product or service is not sold separately during the previous calendar half, then Net Sales Revenue shall be calculated by multiplyin g the Net Sales Revenue of the Combination Product by the fra ction A / C, where is the average gross selling p rice during the previous calendar half of the Licensed P roduct, and is the average gross selling price during the previous calendar half of the Combination Product . In the event that a particular Combination Product is not addressed by the foregoing, then Net Sales Revenue shall be determined by the parties in good faith, t aking into account the relative fair market value contribution of the Licensed Product and the other therapeutica lly active pharmaceutical ingredient, product or service in su ch Combination Product